Analysts expect that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will announce earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Nabriva Therapeutics’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.28). Nabriva Therapeutics reported earnings per share of ($0.41) during the same quarter last year, which indicates a positive year over year growth rate of 19.5%. The company is expected to report its next quarterly earnings results on Tuesday, March 10th.
According to Zacks, analysts expect that Nabriva Therapeutics will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.24) to ($1.05). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.89) per share, with EPS estimates ranging from ($1.02) to ($0.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $6.92 million for the quarter, compared to analysts’ expectations of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%.
A number of analysts have recently issued reports on the company. ValuEngine upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 4th. Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Wednesday. Wedbush restated an “outperform” rating and set a $7.00 price objective on shares of Nabriva Therapeutics in a research report on Friday, November 15th. BidaskClub cut Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Nabriva Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $6.64.
Shares of NBRV traded down $0.02 on Friday, reaching $1.47. 1,440,379 shares of the stock traded hands, compared to its average volume of 1,975,145. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -1.19 and a beta of 2.31. The company has a debt-to-equity ratio of 0.87, a current ratio of 5.81 and a quick ratio of 5.79. Nabriva Therapeutics has a 12 month low of $1.16 and a 12 month high of $3.27. The stock’s 50-day moving average price is $1.54 and its 200-day moving average price is $1.98.
A number of hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its stake in Nabriva Therapeutics by 77.0% in the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock valued at $7,958,000 after buying an additional 1,418,800 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Nabriva Therapeutics by 51.8% in the second quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after purchasing an additional 443,600 shares in the last quarter. Millennium Management LLC boosted its stake in Nabriva Therapeutics by 551.1% in the third quarter. Millennium Management LLC now owns 333,364 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 282,164 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Nabriva Therapeutics by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after purchasing an additional 155,815 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Nabriva Therapeutics by 52.9% in the second quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 91,869 shares in the last quarter. 2.75% of the stock is currently owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.